NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE244387 Query DataSets for GSE244387
Status Public on Apr 02, 2024
Title The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all-trans-retinoic acid
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Rexinoids are agonists of nuclear rexinoid X receptors (RXR) that heterodimerize with other nuclear receptors to regulate gene transcription. A number of selective RXR agonists have been developed for clinical use but their application has been hampered by the unwanted side effects associated with the use of rexinoids and a limited understanding of their mechanisms of action across different cell types. Our previous studies showed that treatment of organotypic human epidermis with the low toxicity UAB30 and UAB110 rexinoids resulted in increased steady-state levels of all-trans-retinoic acid (ATRA), the obligatory ligand of the RXR-RAR heterodimers. Here, we investigated the molecular mechanism underlying the increase in ATRA levels using a dominant negative RXRα that lacks the activation function 2 (AF-2) domain. The results demonstrated that overexpression of dnRXRα in human organotypic epidermis markedly reduced signaling by resident ATRA, suggesting the existence of endogenous RXR ligand, diminished the biological effects of UAB30 and UAB110 on epidermis morphology and gene expression, and nearly abolished the rexinoid-induced increase in ATRA levels. Global transcriptome analysis of dnRXRα-rafts in comparison to empty vector-transduced rafts showed that over 95% of the differentially expressed genes in rexinoid-treated rafts constitute direct or indirect ATRA-regulated genes. Thus, the biological effects of UAB30 and UAB110 are mediated through the AF-2 domain of RXRα with minimal side effects in human epidermis. As ATRA levels are known to be reduced in certain epithelial pathologies, treatment with UAB30 and UAB110 may represent a promising therapy for normalizing the endogenous ATRA concentration and signaling in epithelial tissues.
 
Overall design Transcriptomic profiling of control (CTR) and dominant negative RXRa (dnRXR) human skin rafts treated with UAB30 and UAB110 selective RXR agonists, using high throughput sequencing (Lexogen 3' QuantSeq).
Web link https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0301447
 
Contributor(s) Halasz L, Berger WK, Nagy L
Citation(s) 38557762
Submission date Sep 29, 2023
Last update date Jul 02, 2024
Contact name Laszlo Halasz
E-mail(s) laszlo.halasz@mssm.edu
Phone +17276416811
Organization name Mount Sinai Icahn School of Medicine
Department Department of Oncological Sciences
Lab Dr. Miriam Merad
Street address 1470 Madison Avenue
City New York
State/province NY
ZIP/Postal code 10029
Country USA
 
Platforms (1)
GPL21697 NextSeq 550 (Homo sapiens)
Samples (24)
GSM7814571 Primary keratinocytes, Control untreated replicate 1
GSM7814572 Primary keratinocytes, Control untreated replicate 2
GSM7814573 Primary keratinocytes, Control untreated replicate 3
Relations
BioProject PRJNA1022499

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE244387_count_table_CPM.txt.gz 2.8 Mb (ftp)(http) TXT
GSE244387_count_table_raw.txt.gz 956.0 Kb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap